WuXi Biologics (Cayman) Inc. provided unaudited consolidated earnings guidance for the year ended December 31, 2021. For the period, the company expected that the profit of the Company and the profit attributable to equity shareholders of the Company for the year ended December 31, 2021 will increase more than 105% and more than 98%, respectively, compared with those for the corresponding period of last year.